Author

B. E. Gryder

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 3 Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Assay:scRNA-seq· 2 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

J. Khan· 2 shared A. C. Gross· 1 shared A. G. Sowalsky· 1 shared A. M. Michalowska· 1 shared B. J. Capaldo· 1 shared B. Schaefer· 1 shared B. Z. Stanton· 1 shared C. J. Thomas· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Khan

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Aberrant activation of wound healing programs within the metastatic niche facilitates lung colonization by osteosarcoma cells

J. B. Reinecke, L. Jimenez Garcia, A. C. Gross, M. Cam, M. V. Cannon, M. J. Gust, J. P. Sheridan, B. E. Gryder, R. Dries, R. D. Roberts

This study identifies fibrosis as a targetable vulnerability in osteosarcoma lung metastasis by showing nintedanib inhibits metastatic progression through anti-fibrotic effects.

bioRxiv · Jan 10, 2024Cancer Biology

High-throughput Approaches to Uncover Synergistic Drug Combinations in Leukemia

E. J. Chory, M. Wang, M. Ceribelli, A. M. Michalowska, S. Golas, E. Beck, C. Klumpp-Thomas, L. Chen, C. McKnight, Z. Itkin, S. Divakaran, J. Bradner, J. Khan, B. E. Gryder, C. J. Thomas, B. Z. Stanton

This paper identifies synergistic drug combinations in AML using high-throughput methods and open-source tools, revealing synergies affecting histone H3 lysine-27 modification.

SLAS Discovery · Jun 1, 2023Peer-reviewedCancer Biology

MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity

N. C. Whitlock, S. Y. Trostel, S. Wilkinson, N. T. Terrigino, S. T. Hennigan, R. Lake, N. V. Carrabba, R. Atway, E. D. Walton, B. E. Gryder, B. J. Capaldo, H. Ye, A. G. Sowalsky

This study shows that MYC down-regulates MEIS1 in prostate cancer, which increases AR activity and HOXB13 expression, promoting tumor development.

bioRxiv · Nov 20, 2019Cancer Biology

Miswired enhancer logic drives translocation positive rhabdomyosarcoma

B. E. Gryder, M. Wachtel, K. Chang, O. E. Demerdash, N. G. Aboreden, W. Ewert, S. Pomella, W. Mohammed, R. Rota, J. S. Wei, Y. Song, B. Schaefer, C. R. Vakoc, J. Khan

The paper identifies a miswired enhancer logic driven by PAX3-FOXO1 translocation in rhabdomyosarcoma, disrupting normal transcription factor regulation and promoting undifferentiated proliferation.

bioRxiv · Sep 6, 2019 · PreprintCancer Biology